HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 233/5/592    most recent 0709-RM-259v1 Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Poulsen, R. C. Articles by Kruger, M. C. Search for Related Content PubMed PubMed Citation Articles by Poulsen, R. C. Articles by Kruger, M. C.

---

ORIGINAL RESEARCH ARTICLE

Docosahexaenoic Acid and 17β-Estradiol Co-Treatment Is More Effective Than 17β-Estradiol Alone in Maintaining Bone Post-Ovariectomy

Raewyn C. Poulsen^*, Paul J. Moughan and Marlena C. Kruger^*,1

^* Institute of Food, Nutrition and Human Health, Massey University, Palmerston North 4442, New Zealand; and Riddet Centre, Massey University, Palmerston North 4442, New Zealand

To whom requests for reprints should be addressed at ¹ Institute of Food, Nutrition and Human Health, Massey University, Private Bag 11–222, Palmerston North 4442, New Zealand. E-mail: M.C.Kruger{at}massey.ac.nz

Bone-protective effects of combined treatment with long chain polyunsaturated fatty acids (LCPUFAs) and estrogenic compounds following ovariectomy have previously been reported. Recent evidence suggests the n-3 LCPUFA docosahexaenoic acid (DHA, 22:6n-3) is particularly bone-protective. The aim of this study was to determine whether combined treatment with DHA and estrogenic compounds has a beneficial effect on bone mass in ovariectomized (OVX) rats. Rats were randomized into 9 groups and either ovariectomized (8 groups) or sham-operated (1 group). Using a 2x4 factorial design approach, OVX animals received either no estrogenic compound, genistein (20 mg/kg body weight/day), daidzein, (20 mg/kg body weight/day) or 17β-estradiol (1 µg/day) with or without DHA (0.5 g/kg body weight/day) for 18 weeks. Bone mineral content (BMC), area (BA), and density (BMD), plasma osteocalcin and IL-6 concentrations, and red blood cell (RBC) fatty acid composition were measured. Femur BMC was significantly greater in animals treated with DHA or 17β-estradiol than in ovariectomized controls. Plasma carboxylated osteocalcin was significantly higher in DHA-treated animals and total osteocalcin significantly lower in 17β-estradiol-treated animals compared with ovariectomized controls. There were significant interactions between treatment with estrogenic compounds and DHA for femur BMC, plasma IL-6 concentration, and RBC fatty acid composition. Combined treatment with 17β-estradiol+DHA was more effective than either treatment alone at preserving femur BMC and lowering circulating concentrations of pro-inflammatory IL-6. The percentage of n-3 LCPUFAs in RBCs was significantly greater in animals receiving 17β-estradiol+DHA compared with either treatment alone. There was no beneficial effect of combined DHA and phytoestrogen treatment on bone. Results from this study raise the possibility that co-treatment with 17β-estradiol and DHA may allow a lower dose of 17β-estradiol to be used to provide the same bone-protective effects as when 17β-estradiol is administered alone.

Key Words: isoflavones • n-3 fat • long chain polyunsaturated fatty acids • estrogen • phytoestrogens